Mangoceuticals Inc (MGRX) FinancialsMGRXMangoceuticals Inc

Evaluating the bottom line, Mangoceuticals Inc maintains a gross margin of -342.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1909.52%, while the net margin is -1909.52%. These profitability ratios, combined with a Return on Equity (ROE) of -102.49%, provide a clear picture of how effectively MGRX converts its operational activities into shareholder value.

In the context of the broader market, MGRX competes directly with industry leaders such as XBIO and SKYE. With a market capitalization of $4.44M, it holds a leading position in the sector. When comparing efficiency, MGRX's gross margin of -342.77% stands against XBIO's 100.00% and SKYE's N/A. Such benchmarking helps identify whether Mangoceuticals Inc is trading at a premium or discount relative to its financial performance.

The company's financials show a troubling trend with a net income loss of -1,312,653 USD in Q2 2026 and a gross margin of -342.77%, indicating ongoing financial distress.